Democratizing hedge fund level analysis tools for everyone
| Name | Merck Tbk. |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Health Care Research |
| Code | F2 |
| Latest Quarterly | 06-30-25 |
| Name | Latest % | A Month Ago % |
|---|---|---|
| Merck Holding Gmbh | 74.0 | 74.0 |
| Emedia Export Company Mbh | 13.0 | 13.0 |
| Public < 5% | 13.0 | 13.0 |
| Source | 2022 | 2021 |
|---|---|---|
| MERK | F2 | Biopharma |
| MERK | F2 | Consumer Health |
| MERK | F2 | Other |
| MERK | F2 | Others |
| Region | 2022 | 2021 |
|---|---|---|
| MERK | F2 | Indonesia |
| MERK | F2 | Offshore Countries |
| MERK | F2 | Others |
| Valuation | Ratio | Rank |
|---|---|---|
| P/S | 1.36 | # 9 / 15 |
| EV_EBITDA | 8.02 | # 4 / 15 |
| PER | 10.86 | --- / 15 |
| PBV | 1.72 | # 7 / 15 |
| DER | 0.19 | # 2 / 15 |
| Profitability | Ratio | Rank |
|---|---|---|
| NPM % | 12.540999999999999 | # 3 / 15 |
| ROA % | 13.780000000000001 | # 3 / 15 |
| ROE % | 15.85 | # 6 / 15 |
| Year | DPS | Yield [%] |
|---|---|---|
| 2024 | 640.0 | 17.8 |
| 2023 | 640.0 | 15.4 |
| 2022 | 480.0 | 10.2 |
| 2021 | 244.0 | 6.6 |
| 2020 | 260.0 | 8.0 |
| 2018 | 5650.0 | 198.2 |
| Timeframe | Performance |
|---|---|
| 1W % | 0.9 |
| 1Mo % | 8.6 |
| 3Mo % | 16.6 |
| 1Yr % | 0.6 |
| Stocks | PER | Market Cap | EV | Revenue | EBITDA | Net Profit |
|---|---|---|---|---|---|---|
| KLBF | 16.21 | 56.88 T | 58.14 T | 34,651 B | 5,348 B | 3,508 B |
| SOHO | 30.18 | 17.51 T | 19.64 T | 10,338 B | 711 B | 581 B |
| SIDO | 14.84 | 16.20 T | 15.77 T | 3,639 B | 1,481 B | 1,091 B |
| TSPC | 8.20 | 12.45 T | 10.93 T | 13,512 B | 2,016 B | 1,515 B |
| PYFA | -11.02 | 5.39 T | 11.42 T | 2,747 B | -142 B | -488 B |
| MDLA | 9.50 | 3.67 T | 6.27 T | 14,788 B | 557 B | 386 B |